Skip to main content
. Author manuscript; available in PMC: 2021 Sep 28.
Published in final edited form as: Cancer Lett. 2020 May 30;488:40–49. doi: 10.1016/j.canlet.2020.05.027

Fig. 1. MTM inhibits proliferation of prostate cancer cells and blocks DNA-binding ability of AR-FL and ARvs.

Fig. 1.

A, Crystal violet staining of PCa cells with MTM treatment. B, MTM inhibits cell growth of LNCaP cells. C, MTM inhibits cell growth of AD1 cells D, MTM inhibits cell growth of 22RV1 cells. E, MTM inhibits cell growth of D567 cells. F, Luciferase activity of PSA-ARE in HEK293T cells with overexpressing AR-FL, AR-V7 and ARv567es. G, The effect of MTM on luciferase activity of PSA-ARE in HEK293T cells with overexpressing AR-FL, AR-V7 and ARv567es. H, Luciferase activity of PSA-ARE and FASN-ARE in AD1 cells with MTM treatment. I, Luciferase activity of FASN-ARE in HEK293T cells with overexpressing AR-FL, AR-V7 and ARv567es. J, The effect of MTM on luciferase activity of FASN-ARE in HEK293T cells with overexpressing AR-FL, AR-V7 and ARv567es. K, Luciferase activity of PSA-ARE and FASN-ARE in D567 cells with MTM treatment. L, Effects of DHT and Enzalutamide on the luciferase activity of the PSA-ARE reporter vector in HEK293T cells overexpressing AR-FL. M, Effects of DHT and Enzalutamide and MTM on the luciferase activity of the PSA-ARE reported vector in HEK293T cells overexpressing AR-FL. (For interpretation of the references to color in this figure legend, the reader is referred to the Web version of this article.)